We are inspired by the courage and determination of individuals living with complicated and often difficult-to-treat diseases. We have a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer.
We have been at the forefront of addiction medicine for more than a decade, seeking to help people living with alcohol dependence and opioid dependence.
We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support adults living with schizophrenia and bipolar I disorder.
We are actively researching new immuno-oncology agents for cancer patients in tumor types where we see significant need and opportunity for new treatment options.
Our mission to make innovative medicines that may help address unmet patient needs underlies our work. Our portfolio of proprietary commercial products focuses on chronic, highly prevalent conditions that represent some of the most challenging health issues of our time.
Our research and development efforts are focused on the pursuit of potential new medicines that build on our heritage in neuroscience and, as scientific opportunities present themselves, advancement of our research into important new areas such as immuno-oncology.